このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Maccura BiotechnologyLtd 将来の成長

Future 基準チェック /36

Maccura BiotechnologyLtd利益と収益がそれぞれ年間25.4%と10.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に8% 25.2%なると予測されています。

主要情報

25.4%

収益成長率

25.2%

EPS成長率

Life Sciences 収益成長	28.1%
収益成長率	10.5%
将来の株主資本利益率	8.0%
アナリストカバレッジ	Low
最終更新日	15 May 2024

今後の成長に関する最新情報

Recent updates

Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)

May 28

Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings

May 01

業績と収益の成長予測

SZSE:300463 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,778	664	600	861	3
12/31/2025	3,377	544	348	771	3
12/31/2024	3,059	434	110	718	3
3/31/2024	2,836	316	-255	739	N/A
12/31/2023	2,896	313	24	902	N/A
9/30/2023	3,005	376	-174	856	N/A
6/30/2023	3,207	477	-177	831	N/A
3/31/2023	3,360	623	-62	890	N/A
1/1/2023	3,608	708	-145	843	N/A
9/30/2022	3,690	761	620	1,342	N/A
6/30/2022	3,802	831	912	1,590	N/A
3/31/2022	3,836	845	1,037	1,650	N/A
1/1/2022	3,981	957	1,015	1,617	N/A
9/30/2021	4,184	1,024	887	1,608	N/A
6/30/2021	4,212	1,015	714	1,379	N/A
3/31/2021	4,255	1,032	546	1,109	N/A
12/31/2020	3,704	794	593	1,094	N/A
9/30/2020	3,405	677	388	738	N/A
6/30/2020	3,158	565	258	589	N/A
3/31/2020	3,019	482	128	578	N/A
12/31/2019	3,223	525	-45	460	N/A
9/30/2019	3,078	504	-245	239	N/A
6/30/2019	2,956	483	-247	284	N/A
3/31/2019	2,889	463	-281	240	N/A
12/31/2018	2,685	445	-336	194	N/A
9/30/2018	2,568	431	-392	114	N/A
6/30/2018	2,373	413	-459	37	N/A
3/31/2018	2,126	394	-460	15	N/A
12/31/2017	1,970	374	N/A	79	N/A
9/30/2017	1,798	365	N/A	86	N/A
6/30/2017	1,663	340	N/A	88	N/A
3/31/2017	1,570	324	N/A	95	N/A
12/31/2016	1,489	312	N/A	49	N/A
9/30/2016	1,364	303	N/A	6	N/A
6/30/2016	1,220	279	N/A	-10	N/A
3/31/2016	1,139	271	N/A	14	N/A
12/31/2015	1,065	251	N/A	33	N/A
9/30/2015	1,024	244	N/A	101	N/A
6/30/2015	997	243	N/A	52	N/A
3/31/2015	959	231	N/A	139	N/A
12/31/2014	935	226	N/A	115	N/A
12/31/2013	779	193	N/A	98	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 300463の予測収益成長率 (年間25.4% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 300463の収益 ( 25.4% ) はCN市場 ( 22.8% ) よりも速いペースで成長すると予測されています。

高成長収益: 300463の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 300463の収益 ( 10.5% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 300463の収益 ( 10.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 300463の自己資本利益率は、3年後には低くなると予測されています ( 8 %)。

Maccura BiotechnologyLtd 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 17%

Price target decreased by 21% to CN¥20.86

Price target increased to CN¥26.33

Consensus revenue estimates fall by 18%

Price target raised to CN¥62.32

Recent updates

Maccura Biotechnology Co.Ltd to Report First Half, 2024 Results on Aug 02, 2024

Maccura Biotechnology Co.Ltd Announces Final Profit Distribution Plan on A Shares for the Year 2023, Payable on July 3, 2024

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2023

Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)

Maccura Biotechnology Co.Ltd, Annual General Meeting, Jun 03, 2024

Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings

Maccura Biotechnology Co.Ltd Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.19 in 1Q 2023)

Maccura Biotechnology Co.Ltd to Report Q1, 2024 Results on Apr 25, 2024

Maccura Biotechnology Co.Ltd (SZSE:300463) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment deteriorates as stock falls 19%

Maccura Biotechnology Co.Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Maccura Biotechnology Co.Ltd(SZSE:300463) dropped from Shenzhen Stock Exchange Component A Share Index

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.32 in 3Q 2022)

Consensus EPS estimates fall by 17%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.095 (vs CN¥0.33 in 2Q 2022)

Maccura Biotechnology Co.Ltd to Report First Half, 2023 Results on Jul 29, 2023

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2022

Price target decreased by 21% to CN¥20.86

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.34 in 1Q 2022)

Price target increased to CN¥26.33

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.48 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in 2Q 2021)

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2021

Maccura Biotechnology Co.Ltd Approves Cash Dividend of for 202

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.48 (vs CN¥0.46 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.42 in 2Q 2020)

Maccura Biotechnology Co.Ltd Approves Final Dividend for the Year 2020

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.14 in 1Q 2020)

Maccura Biotechnology Co.Ltd (SZSE:300463) announces an Equity Buyback for CNY 300 million worth of its shares.

New 90-day low: CN¥39.84

New 90-day low: CN¥41.24

New 90-day low: CN¥45.38

Price target raised to CN¥62.32

Third quarter earnings released

Maccura Biotechnology Co.Ltd announced that it expects to receive CNY 2.77 billion in funding

Maccura Biotechnology Co.Ltd to Report First Half, 2020 Results on Jul 31, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘